Tag: #drugresistance

In the four decades since the molecular basis of cancer began to yield to systematic investigation, one finding has proved both illuminating and clinically frustrating in equal measure: the genetic heterogeneity of drug resistance. In melanoma alone, resistance to the BRAF inhibitor vemurafenib — the first targeted therapy approved for this malignancy — has been…